Literature DB >> 11777947

Potent CD4+ T cell responses elicited by a bicistronic HIV-1 DNA vaccine expressing gp120 and GM-CSF.

Dan H Barouch1, Sampa Santra, Klara Tenner-Racz, Paul Racz, Marcelo J Kuroda, Joern E Schmitz, Shawn S Jackson, Michelle A Lifton, Dan C Freed, Helen C Perry, Mary-Ellen Davies, John W Shiver, Norman L Letvin.   

Abstract

Virus-specific CD4(+) T cell responses have been shown to play a critical role in controlling HIV-1 replication. Candidate HIV-1 vaccines should therefore elicit potent CD4(+) as well as CD8(+) T cell responses. In this report we investigate the ability of plasmid GM-CSF to augment CD4(+) T cell responses elicited by an HIV-1 gp120 DNA vaccine in mice. Coadministration of a plasmid expressing GM-CSF with the gp120 DNA vaccine led to only a marginal increase in gp120-specific splenocyte CD4(+) T cell responses. However, immunization with a bicistronic plasmid that coexpressed gp120 and GM-CSF under control of a single promoter led to a dramatic augmentation of vaccine-elicited CD4(+) T cell responses, as measured by both cellular proliferation and ELISPOT assays. This augmentation of CD4(+) T cell responses was selective, since vaccine-elicited Ab and CD8(+) T cell responses were not significantly changed by the addition of GM-CSF. A 100-fold lower dose of the gp120/GM-CSF bicistronic DNA vaccine was required to elicit detectable gp120-specific splenocyte proliferative responses compared with the monocistronic gp120 DNA vaccine. Consistent with these findings, i.m. injection of the gp120/GM-CSF bicistronic DNA vaccine evoked a more extensive cellular infiltrate at the site of inoculation than the monocistronic gp120 DNA vaccine. These results demonstrate that bicistronic DNA vaccines containing GM-CSF elicit remarkably potent CD4(+) T cell responses and suggest that optimal Th cell priming requires the precise temporal and spatial codelivery of Ag and GM-CSF.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11777947     DOI: 10.4049/jimmunol.168.2.562

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  55 in total

1.  A chimeric HIV-1 envelope glycoprotein trimer with an embedded granulocyte-macrophage colony-stimulating factor (GM-CSF) domain induces enhanced antibody and T cell responses.

Authors:  Thijs van Montfort; Mark Melchers; Gözde Isik; Sergey Menis; Po-Ssu Huang; Katie Matthews; Elizabeth Michael; Ben Berkhout; William R Schief; John P Moore; Rogier W Sanders
Journal:  J Biol Chem       Date:  2011-04-22       Impact factor: 5.157

2.  Enhancement of gp120-specific immune responses by genetic vaccination with the human immunodeficiency virus type 1 envelope gene fused to the gene coding for soluble CTLA4.

Authors:  Bishnu P Nayak; Gangadhara Sailaja; Abdul M Jabbar
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

3.  Plasmid chemokines and colony-stimulating factors enhance the immunogenicity of DNA priming-viral vector boosting human immunodeficiency virus type 1 vaccines.

Authors:  Dan H Barouch; Paul F McKay; Shawn M Sumida; Sampa Santra; Shawn S Jackson; Darci A Gorgone; Michelle A Lifton; Bimal K Chakrabarti; Ling Xu; Gary J Nabel; Norman L Letvin
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

4.  Neutralizing antibodies and CD8+ T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors.

Authors:  Shawn M Sumida; Diana M Truitt; Michael G Kishko; Janelle C Arthur; Shawn S Jackson; Darci A Gorgone; Michelle A Lifton; Wouter Koudstaal; Maria G Pau; Stefan Kostense; Menzo J E Havenga; Jaap Goudsmit; Norman L Letvin; Dan H Barouch
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

5.  Lessons in nonhuman primate models for AIDS vaccine research: from minefields to milestones.

Authors:  Jeffrey D Lifson; Nancy L Haigwood
Journal:  Cold Spring Harb Perspect Med       Date:  2012-06       Impact factor: 6.915

6.  Suppression of major histocompatibility complex class II-associated invariant chain enhances the potency of an HIV gp120 DNA vaccine.

Authors:  Xueqing Lu; Shuzhen Wu; Catherine E Blackwell; Robert E Humphreys; Eric von Hofe; Minzhen Xu
Journal:  Immunology       Date:  2006-11-20       Impact factor: 7.397

7.  Cellular immunity elicited by human immunodeficiency virus type 1/ simian immunodeficiency virus DNA vaccination does not augment the sterile protection afforded by passive infusion of neutralizing antibodies.

Authors:  John R Mascola; Mark G Lewis; Thomas C VanCott; Gabriela Stiegler; Hermann Katinger; Michael Seaman; Kristin Beaudry; Dan H Barouch; Birgit Korioth-Schmitz; Georgia Krivulka; Anna Sambor; Brent Welcher; Daniel C Douek; David C Montefiori; John W Shiver; Pascal Poignard; Dennis R Burton; Norman L Letvin
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

8.  Vaccination of cats with attenuated feline immunodeficiency virus proviral DNA vaccine expressing gamma interferon.

Authors:  Soumi Gupta; Christian M Leutenegger; Gregg A Dean; Jonathan D Steckbeck; Kelly Stefano Cole; Ellen E Sparger
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

9.  Bicistronic woodchuck hepatitis virus core and gamma interferon DNA vaccine can protect from hepatitis but does not elicit sterilizing antiviral immunity.

Authors:  Jinguo Wang; Shashi A Gujar; Lucyna Cova; Tomasz I Michalak
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

Review 10.  Novel GM-CSF-based vaccines: One small step in GM-CSF gene optimization, one giant leap for human vaccines.

Authors:  Ting-Wei Yu; Ho-Yen Chueh; Ching-Chou Tsai; Cheng-Tao Lin; Jiantai Timothy Qiu
Journal:  Hum Vaccin Immunother       Date:  2016-08-25       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.